362 related articles for article (PubMed ID: 21924545)
1. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort.
Hambrock T; Hoeks C; Hulsbergen-van de Kaa C; Scheenen T; Fütterer J; Bouwense S; van Oort I; Schröder F; Huisman H; Barentsz J
Eur Urol; 2012 Jan; 61(1):177-84. PubMed ID: 21924545
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging‑directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12‑core transrectal ultrasound‑guided prostate biopsy.
Zhang J; Xiu J; Dong Y; Wang M; Han X; Qin Y; Huang Z; Cai S; Yuan X; Liu Q
Mol Med Rep; 2014 May; 9(5):1989-97. PubMed ID: 24584266
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.
Arsov C; Rabenalt R; Blondin D; Quentin M; Hiester A; Godehardt E; Gabbert HE; Becker N; Antoch G; Albers P; Schimmöller L
Eur Urol; 2015 Oct; 68(4):713-20. PubMed ID: 26116294
[TBL] [Abstract][Full Text] [Related]
5. Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness.
Li C; Chen M; Wang J; Wang X; Zhang W; Zhang C
Acta Radiol; 2017 Feb; 58(2):232-239. PubMed ID: 27055916
[TBL] [Abstract][Full Text] [Related]
6. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
7. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients.
Baco E; Ukimura O; Rud E; Vlatkovic L; Svindland A; Aron M; Palmer S; Matsugasumi T; Marien A; Bernhard JC; Rewcastle JC; Eggesbø HB; Gill IS
Eur Urol; 2015 Apr; 67(4):787-94. PubMed ID: 25240973
[TBL] [Abstract][Full Text] [Related]
9. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series.
Somford DM; Hambrock T; Hulsbergen-van de Kaa CA; Fütterer JJ; van Oort IM; van Basten JP; Karthaus HF; Witjes JA; Barentsz JO
Invest Radiol; 2012 Mar; 47(3):153-8. PubMed ID: 22293513
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
Siddiqui MM; Rais-Bahrami S; Truong H; Stamatakis L; Vourganti S; Nix J; Hoang AN; Walton-Diaz A; Shuch B; Weintraub M; Kruecker J; Amalou H; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
Eur Urol; 2013 Nov; 64(5):713-719. PubMed ID: 23787357
[TBL] [Abstract][Full Text] [Related]
12. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
[TBL] [Abstract][Full Text] [Related]
13. Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies.
Sheikh N; Wei C; Szewczyk-Bieda M; Campbell A; Memon S; Lang S; Nabi G
World J Urol; 2017 Feb; 35(2):213-220. PubMed ID: 27236302
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
[TBL] [Abstract][Full Text] [Related]
15. Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours.
Bittencourt LK; Barentsz JO; de Miranda LC; Gasparetto EL
Eur Radiol; 2012 Feb; 22(2):468-75. PubMed ID: 21913058
[TBL] [Abstract][Full Text] [Related]
16. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
17. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy.
Komai Y; Numao N; Yoshida S; Matsuoka Y; Nakanishi Y; Ishii C; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
J Urol; 2013 Sep; 190(3):867-73. PubMed ID: 23542406
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
[TBL] [Abstract][Full Text] [Related]
19. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
Schouten MG; van der Leest M; Pokorny M; Hoogenboom M; Barentsz JO; Thompson LC; Fütterer JJ
Eur Urol; 2017 Jun; 71(6):896-903. PubMed ID: 28063613
[TBL] [Abstract][Full Text] [Related]
20. ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasound-Guided Biopsy.
Sadoughi N; Krishna S; McInnes MDF; Flood TA; Breau RH; Morash C; Schieda N
AJR Am J Roentgenol; 2018 Sep; 211(3):W158-W165. PubMed ID: 29995495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
